5.17

2.27% -0.12

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is currently priced at $5.17, with a 24-hour trading volume of 215.50K. It has seen a -2.27% decreased in the last 24 hours and a -0.58% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.25 pivot point. If it approaches the $5.08 support level, significant changes may occur.

Previous Close:

$5.29

Open:

$5.25

24h Volume:

215.50K

Market Cap:

$164.47M

Revenue:

$25.18M

Net Income/Loss:

$-22.29M

P/E Ratio:

-4.4188

EPS:

-1.17

Net Cash Flow:

$-27.64M

1W Performance:

-1.34%

1M Performance:

-0.58%

6M Performance:

+21.93%

1Y Performance:

+8.39%

1D Range:

$5.03

$5.3487

52W Range:

$2.68

$8.2212

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

310-358-3200

Address

8840 Wilshire Boulevard, 2nd Floor, Beverly Hills, CA

Employee

Twitter

@Capricor

Next Earnings Date

2024-05-13

Latest SEC Filings

CAPR's Discussions on Twitter

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

The Significance of Moving Averages in Capricor Therapeutics Inc Inc. (CAPR) Price Performance - The InvestChronicle

The InvestChronicle

Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal

Zacks Investment Research

Pfizer's Duchenne gene therapy fails in late-stage study - Yahoo News Canada

Yahoo News Canada

Potash America (OTCMKTS:PTAM) Stock Price Crosses Above 50 Day Moving Average of $0.00 - Defense World

Defense World

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average of $5.70 - Defense World

Defense World

Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $5.70 - MarketBeat

MarketBeat

Capricor Therapeutics Inc Stock (CAPR) Financials Data

Capricor Therapeutics Inc (CAPR) Revenue 2024

CAPR reported a revenue (TTM) of $25.18 million for the quarter ending December 31, 2023.

Capricor Therapeutics Inc (CAPR) Net Income 2024

CAPR net income (TTM) was -$22.29 million for the quarter ending December 31, 2023, a +23.20% increase year-over-year.

Capricor Therapeutics Inc (CAPR) Cash Flow 2024

CAPR recorded a free cash flow (TTM) of -$27.64 million for the quarter ending December 31, 2023, a -1,876% decrease year-over-year.

Capricor Therapeutics Inc (CAPR) Earnings per Share 2024

CAPR earnings per share (TTM) was -$0.83 for the quarter ending December 31, 2023, a +29.66% growth year-over-year.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Its development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.